{"organizations": [], "uuid": "66b826a85be2630feb3a1514b6ef4ce9d497c47d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-edwards-lifesciences-reports-q1-ea/brief-edwards-lifesciences-reports-q1-earnings-of-0-96-share-idUSB8N1LI03J", "country": "US", "domain_rank": 408, "title": "BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-04-25T04:29:00.000+03:00", "replies_count": 0, "uuid": "66b826a85be2630feb3a1514b6ef4ce9d497c47d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-edwards-lifesciences-reports-q1-ea/brief-edwards-lifesciences-reports-q1-earnings-of-0-96-share-idUSB8N1LI03J", "ord_in_thread": 0, "title": "BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share", "locations": [], "entities": {"persons": [{"name": "edwards", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "edwards lifesciences corp", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Edwards Lifesciences Corp:\n* QUARTERLY SALES $894.8 MILLION, UP 1.3 PERCENT * QUARTERLY TOTAL ADJUSTED SALES $937.5 MILLION, UP 9.3 PERCENT\n* EDWARDS LIFESCIENCES CORP Q1 EARNINGS PER SHARE VIEW $1.11, REVENUE VIEW $932.9 MILLION — THOMSON REUTERS I/B/E/S\n* QUARTERLY TRANSCATHETER HEART VALVE THERAPY SALES OF $551.6 MILLION, UP 2.3 PERCENT\n* SAYS 2018 ADJUSTED EARNINGS PER SHARE OUTLOOK RAISED TO $4.50 TO $4.70 FROM $4.43 TO $4.63\n* SAYS REMAINS CONFIDENT IN ACHIEVING HIGHER END OF 2018 SALES OUTLOOK RANGE OF $3.5 BILLION TO $3.9 BILLION\n* EDWARDS LIFESCIENCES CORP FY2018 EARNINGS PER SHARE VIEW $4.53, REVENUE VIEW $3.85 BILLION — THOMSON REUTERS I/B/E/S\n* EDWARDS LIFESCIENCES CORP Q2 EARNINGS PER SHARE VIEW $1.17, REVENUE VIEW $967.0 MILLION — THOMSON REUTERS I/B/E/S\n* SAYS FOR Q2, PROJECTS TOTAL SALES TO BE $950 MILLION TO $1 BILLION AND ADJUSTED EARNINGS PER SHARE OF $1.05 TO $1.15\n* SAYS CONTINUES TO EXPECT THVT FY UNDERLYING SALES GROWTH RATE TO BE AT HIGHER END OF 11 PERCENT TO 15 PERCENT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T04:29:00.000+03:00", "crawled": "2018-04-25T14:22:33.002+03:00", "highlightTitle": ""}